FDA grants Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer August 6, 2024
RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study July 23, 2024
Application filed for for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer July 17, 2024
Third Independent Safety Review of Ph 3 ASPIRE Clinical Trial Announced; DSMB Recommended Continuation with No Trial Modification July 1, 2024
Substantial OS Benefit and Unprecedented DoR in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Ph 2 Study in 1L Pancreatic Cancer Announced July 1, 2024
Data from 1-BETTER Ph 1/2 study for advanced pancreatic cancer of Natrunix + ONIVYDE/5-FU announced June 25, 2024
Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer June 18, 2024
Positive Initial Interim Safety and Efficacy Results Announced from RAMP 205 Trial of Avutometinib, Defactinib, Gemcitabine and Nab-paclitaxel combo in 1L Metastatic Pancreatic Cancer May 29, 2024
Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer May 29, 2024
Ph 2/3 Trial of Surufatinib + Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui Initiated May 21, 2024
Paediatric Investigation Plan Waiver Received from the European Medicines Agency for Certepetide in Pancreatic Cancer May 21, 2024
U.S. FDA Accepts and grants Priority Review of BLA for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 15, 2024
First Dose Level found to be Generally Well-Tolerated in Ph 1b/2 Study of Ampligen and Imfinzi Combination for Late-Stage Pancreatic Cancer May 1, 2024
FDA approves Lutathera® for pediatric patients with gastroenteropancreatic neuroendocrine tumors May 1, 2024
Positive Interim Data Announced from Randomized Ph 2 Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer April 8, 2024
Positive Findings announced from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research March 26, 2024
PT886 granted Fast Track designation for the treatment of patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA March 26, 2024
